Alphamab Oncology

Informe acción SEHK:9966

Capitalización de mercado: HK$3.7b

Alphamab Oncology Dirección

Dirección controles de criterios 2/4

Alphamab Oncology's CEO is Ting Xu, appointed in Nov 2008, has a tenure of 6.67 years. total yearly compensation is CN¥6.88M, comprised of 95.2% salary and 4.8% bonuses, including company stock and options. directly owns 33.06% of the company’s shares, worth HK$1.23B. The average tenure of the management team and the board of directors is 5.8 years and 5 years respectively.

Información clave

Ting Xu

Chief Executive Officer (CEO)

CN¥6.9m

Compensación total

Porcentaje del salario del CEO95.2%
Permanencia del CEO16yrs
Participación del CEO33.1%
Permanencia media de la dirección5.8yrs
Promedio de permanencia en la Junta Directiva5yrs

Actualizaciones recientes de la dirección

Recent updates

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Sep 30
Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Jun 20
Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06
Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17
Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21
Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01
Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Oct 04
Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Is Alphamab Oncology (HKG:9966) A Risky Investment?

May 21
Is Alphamab Oncology (HKG:9966) A Risky Investment?

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Oct 05
Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

May 05
Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ting Xu en comparación con los beneficios de Alphamab Oncology?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

-CN¥216m

Mar 31 2024n/an/a

-CN¥213m

Dec 31 2023CN¥7mCN¥7m

-CN¥211m

Sep 30 2023n/an/a

-CN¥214m

Jun 30 2023n/an/a

-CN¥218m

Mar 31 2023n/an/a

-CN¥272m

Dec 31 2022CN¥7mCN¥6m

-CN¥326m

Sep 30 2022n/an/a

-CN¥309m

Jun 30 2022n/an/a

-CN¥292m

Mar 31 2022n/an/a

-CN¥352m

Dec 31 2021CN¥7mCN¥5m

-CN¥412m

Sep 30 2021n/an/a

-CN¥502m

Jun 30 2021n/an/a

-CN¥592m

Mar 31 2021n/an/a

-CN¥510m

Dec 31 2020CN¥5mCN¥4m

-CN¥428m

Sep 30 2020n/an/a

-CN¥652m

Jun 30 2020n/an/a

-CN¥877m

Mar 31 2020n/an/a

-CN¥851m

Dec 31 2019CN¥5mCN¥3m

-CN¥833m

Compensación vs. Mercado: Ting's total compensation ($USD969.67K) is above average for companies of similar size in the Hong Kong market ($USD399.57K).

Compensación vs. Ingresos: Ting's compensation has increased whilst the company is unprofitable.


CEO

Ting Xu (51 yo)

16yrs

Permanencia

CN¥6,877,000

Compensación

Dr. Ting Xu, Ph D., serves Chief Executive Officer at Alphamab Oncology since October 1, 2018. He Founded Alphamab Oncology in November 2008.Dr. Xu serves as Executive Director at Alphamab Oncology since...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Ting Xu
Founder16yrsCN¥6.88m33.06%
HK$ 1.2b
Yang Liu
VP of Corporate Operations & Executive Director6.1yrsCN¥2.97msin datos
Yumin Wan
Vice President of Government Affairs & Public Relations5.8yrssin datossin datos
Mike Liu
Senior Vice President of Business Development6.5yrssin datossin datos
Jing Han
Chief Commercial Officer3yrssin datossin datos
Lok Yee Chan
Joint Company Secretary4.3yrssin datossin datos
Qiulan Cheng
Joint Company Secretaryless than a yearsin datossin datos

5.8yrs

Permanencia media

51.5yo

Promedio de edad

Equipo directivo experimentado: 9966's management team is seasoned and experienced (5.8 years average tenure).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Ting Xu
Founder6.7yrsCN¥6.88m33.06%
HK$ 1.2b
Yang Liu
VP of Corporate Operations & Executive Director6.1yrsCN¥2.97msin datos
Cheng Wei
Independent Non-Executive Director5yrsCN¥396.00ksin datos
Man Cho
Non-Executive Directorless than a yearsin datos0.11%
HK$ 4.0m
Jason J. Luke
Member of Scientific Advisory Boardno datasin datossin datos
Yiping Yang
Member of Scientific Advisory Boardno datasin datossin datos
Dong Wu
Independent Non-Executive Director5yrsCN¥396.00ksin datos
Lei Zheng
Member of Scientific Advisory Boardno datasin datossin datos
Zihai Li
Chairman of Scientific Advisory Boardno datasin datossin datos
Zijian Guo
Independent Non-Executive Director3.3yrsCN¥378.00ksin datos

5.0yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: 9966's board of directors are considered experienced (5 years average tenure).